Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Latin America Health Times.
Press releases published on April 15, 2025
MEDĀNA ENTRA EN EL MERCADO ESPAÑOL CON UNA PLATAFORMA DE IA PARA TRANSFORMAR LA SANIDAD EN TODA EUROPA
GlobeNewswire
·
April 15, 2025
LISBOA, Portugal, April 15, 2025 (GLOBE NEWSWIRE) -- España está a punto de recibir una de las tecnologías más disruptivas en salud digital. Medāna (www.medana.ai), startup internacional fundada por la Dra. Tal Patalon, ha anunciado su entrada estratégica …
Medāna Enters the Netherlands Market with an AI Platform to Transform Healthcare Across Europe
GlobeNewswire
·
April 15, 2025
LISBON, Portugal, April 15, 2025 (GLOBE NEWSWIRE) -- Netherlands is about to welcome one of the most disruptive technologies in digital health. Medāna (www.medana.ai), the global startup founded by Dr. Tal Patalon, has announced its strategic entry into …
MEDĀNA BETREEDT DE NEDERLANDSE MARKT MET EEN AI-PLATFORM OM DE GEZONDHEIDSZORG TE TRANSFORMEREN IN EUROPA
GlobeNewswire
·
April 15, 2025
LISSABON, Portugal, April 15, 2025 (GLOBE NEWSWIRE) -- Nederland staat op het punt een van de meest baanbrekende technologieën in de digitale gezondheidszorg te verwelkomen. Medāna (www.medana.ai), de startup opgericht door Dr. Tal Patalon, heeft zijn …
Genenta Showcases Strategic Vision at Premier Biotech Forum in Qatar
GlobeNewswire
·
April 15, 2025
MILAN and NEW YORK, April 15, 2025 (GLOBE NEWSWIRE) -- Pierluigi Paracchi, CEO Genenta Science (Nasdaq: GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, will present at “Montalcini Global Biotech Tour” in Doha, Qatar on April …
HepaRegeniX completes €21.5 million financing to support clinical advancement of HRX-215 for liver regeneration
GlobeNewswire
·
April 15, 2025
Tuebingen, Germany, April 15, 2025 – HepaRegeniX GmbH (“HepaRegeniX”), a clinical-stage company advancing novel therapies to treat acute and chronic liver diseases, today announced the second closing and completion of a €21.5 million financing round with …
Oculis Hosts R&D Event Today to Showcase Progress on All Three Pipeline Assets
GlobeNewswire
·
April 15, 2025
ZUG, Switzerland, April 15, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company"), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant …
Concept Life Sciences expands expertise with key appointments to Scientific Advisory Board and investments to strengthen integrated drug discovery capabilities
GlobeNewswire
·
April 15, 2025
CHAPEL-EN-LE-FRITH, United Kingdom, April 15, 2025 (GLOBE NEWSWIRE) -- Concept Life Sciences (CLS), a leading integrated drug discovery, development, and manufacturing organisation backed by Limerston Capital, today announced key strategic appointments and …
Cyprumed Enters License and Option Agreement with MSD for the Development of Oral Peptide Therapeutics
GlobeNewswire
·
April 15, 2025
MSD obtains a Non-Exclusive License for Cyprumed’s delivery technology to develop oral peptide therapeutics Cyprumed will be eligible to receive up to $493 million in upfront, development, regulatory and sales milestones INNSBRUCK, Austria, April 15, 2025 …
1ST Biotherapeutics Joins The Michael J. Fox Foundation’s LITE Program to Advance LRRK2-Based Parkinson’s Disease Research
GlobeNewswire
·
April 15, 2025
Focus on the discovery of next-generation LRRK2 inhibitors to unlock novel biological mechanisms of action and advance new treatment options YONGIN, South Korea, April 15, 2025 – 1ST Biotherapeutics, Inc. (1STBIO), a clinical-stage biopharmaceutical …
Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases
GlobeNewswire
·
April 15, 2025
Partnership bolsters Boehringer’s autoimmune and inflammatory disease pipeline portfolio aiming to tackle areas of high unmet patient need. The agreement focuses on further research and development of a novel, first-in-class bispecific …
CORXEL Receives Study May Proceed Letter from the U.S. FDA for the Phase 2 Trial of CX11 in Patients with Obesity and Overweight Conditions
GlobeNewswire
·
April 15, 2025
The U.S. Phase 2 trial aims to evaluate efficacy and safety of CX11 in doses up to 200 mg and different titration schemes The trial is expected to enroll 250 patients to receive treatment over 36 weeks BERKELEY HEIGHTS, N.J., April 15, 2025 (GLOBE NEWSWIRE …
Galapagos Announces Departure of Thad Huston, CFO and COO, as of August 1, 2025
GlobeNewswire
·
April 15, 2025
Mechelen, Belgium; April 15, 2025, 07:30 CET; regulated information – inside information – Galapagos NV (Euronext …
Galapagos kondigt het vertrek van haar CFO en COO, Thad Huston, aan per 1 augustus 2025
GlobeNewswire
·
April 15, 2025
Mechelen, België; 15 april 2025, 07:30 CET; gereglementeerde informatie - voorwetenschap – Galapagos NV (Euronext …
Press Release: Sanofi’s respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD
GlobeNewswire
·
April 15, 2025
Sanofi’s respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD New phase 2 data for amlitelimab show efficacy in heterogeneous inflammatory asthma Lunsekimig now targeting chronic rhinosinusitis and COPD in …
Communiqué de presse : Le portefeuille de traitements contre les maladies respiratoires de Sanofi s’enrichit de nouvelles données sur l’asthme et prévoit de nouvelles études cliniques sur la BPCO
GlobeNewswire
·
April 15, 2025
Le portefeuille de traitements contre les maladies respiratoires de Sanofi s’enrichit de nouvelles données sur l’asthme et prévoit de nouvelles études cliniques sur la BPCO De nouvelles données de phase II démontrent l’efficacité de l’amlitélimab dans le …
Kuros Biosciences reports 82% year over year increase in sales in the first three months of 2025
GlobeNewswire
·
April 15, 2025
Ad hoc announcement pursuant to Article 53 of the SIX listing rules Kuros Biosciences reports 82% year over year increase in sales in the first three months of 2025 Financial …
Cue Biopharma Announces Pricing of Approximately $20 Million Public Offering
GlobeNewswire
·
April 15, 2025
BOSTON, April 14, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of …